3 SEHK Stocks Estimated To Be Trading Below Their Intrinsic Value

In This Article:

The Hong Kong stock market has recently experienced a notable surge, buoyed by China's comprehensive stimulus measures aimed at revitalizing its economy. This positive sentiment has created an opportune environment for investors to explore stocks that may be trading below their intrinsic value. In the current market landscape, identifying undervalued stocks involves looking for companies with strong fundamentals that have not yet been fully recognized by the broader market.

Top 10 Undervalued Stocks Based On Cash Flows In Hong Kong

Name

Current Price

Fair Value (Est)

Discount (Est)

BYD Electronic (International) (SEHK:285)

HK$32.55

HK$64.40

49.5%

Giant Biogene Holding (SEHK:2367)

HK$50.95

HK$97.67

47.8%

Alibaba Health Information Technology (SEHK:241)

HK$5.35

HK$10.01

46.6%

XD (SEHK:2400)

HK$25.50

HK$47.75

46.6%

China Ruyi Holdings (SEHK:136)

HK$2.26

HK$4.16

45.6%

Shanghai INT Medical Instruments (SEHK:1501)

HK$28.70

HK$56.43

49.1%

Zylox-Tonbridge Medical Technology (SEHK:2190)

HK$13.00

HK$25.94

49.9%

Digital China Holdings (SEHK:861)

HK$2.96

HK$5.86

49.5%

Akeso (SEHK:9926)

HK$68.60

HK$134.24

48.9%

Hua Hong Semiconductor (SEHK:1347)

HK$20.90

HK$38.48

45.7%

Click here to see the full list of 40 stocks from our Undervalued SEHK Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Giant Biogene Holding

Overview: Giant Biogene Holding Co., Ltd. is an investment holding company involved in the research, development, manufacture, and sale of bioactive material-based beauty and health products in China, with a market cap of HK$51.42 billion.

Operations: The company generates revenue primarily from its biotechnology segment, which amounted to CN¥4.46 billion.

Estimated Discount To Fair Value: 47.8%

Giant Biogene Holding is trading at 47.8% below its estimated fair value of HK$97.67, supported by strong cash flows and a recent earnings report showing net income growth to CNY 983.16 million for H1 2024 from CNY 666.94 million a year ago. The company's revenue and profit are forecast to grow significantly faster than the Hong Kong market, driven by innovative product launches like the Vpro skincare line featuring advanced recombinant collagen technology.

SEHK:2367 Discounted Cash Flow as at Sep 2024
SEHK:2367 Discounted Cash Flow as at Sep 2024

BYD Electronic (International)

Overview: BYD Electronic (International) Company Limited designs, manufactures, assembles, and sells mobile handset components and modules both in China and internationally, with a market cap of HK$73.34 billion.